DE3685833T2 - Dns-vakzine. - Google Patents

Dns-vakzine.

Info

Publication number
DE3685833T2
DE3685833T2 DE8686104498T DE3685833T DE3685833T2 DE 3685833 T2 DE3685833 T2 DE 3685833T2 DE 8686104498 T DE8686104498 T DE 8686104498T DE 3685833 T DE3685833 T DE 3685833T DE 3685833 T2 DE3685833 T2 DE 3685833T2
Authority
DE
Germany
Prior art keywords
dns
vaccine
dns vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686104498T
Other languages
English (en)
Other versions
DE3685833D1 (de
Inventor
Hendrik Gerard Stunnenberg
Riccardo Wittek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE3685833D1 publication Critical patent/DE3685833D1/de
Publication of DE3685833T2 publication Critical patent/DE3685833T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE8686104498T 1985-04-04 1986-04-02 Dns-vakzine. Expired - Fee Related DE3685833T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858508845A GB8508845D0 (en) 1985-04-04 1985-04-04 Vaccinia dna

Publications (2)

Publication Number Publication Date
DE3685833D1 DE3685833D1 (de) 1992-08-06
DE3685833T2 true DE3685833T2 (de) 1992-12-17

Family

ID=10577216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686104498T Expired - Fee Related DE3685833T2 (de) 1985-04-04 1986-04-02 Dns-vakzine.

Country Status (9)

Country Link
US (1) US5017487A (de)
EP (1) EP0198328B1 (de)
JP (2) JPS61289888A (de)
AU (1) AU595190B2 (de)
CA (1) CA1316849C (de)
DE (1) DE3685833T2 (de)
DK (1) DK112586A (de)
GB (1) GB8508845D0 (de)
ZA (1) ZA862356B (de)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243029A1 (de) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Rekombinantes Vaccinia-Virus, das ein menschliches Retrovirus-Gen ausdrückt
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5348741A (en) * 1987-02-03 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Vector for recombinant poxvirus expressing rabies virus glycoprotein
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
CA2035039C (en) * 1989-06-21 2000-02-01 Vincent A. Fischetti Recombinant poxvirus and streptococcal m protein vaccine
WO1991011519A1 (en) * 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
JPH06505397A (ja) * 1991-03-20 1994-06-23 ヴァイロジェネティクス　コーポレイション マラリア組換体ポックスウイルス
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69434469T2 (de) * 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
DE69535288T2 (de) * 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
AUPN658795A0 (en) * 1995-11-15 1995-12-07 Commonwealth Scientific And Industrial Research Organisation Method of producing alpha 2, 3 sialyltransferase
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2254082C (en) * 1996-05-03 2012-09-11 Thomas Jefferson University Metastatic colorectal cancer vaccine
EP2298900A1 (de) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
EP2386630A1 (de) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidinkinasemutanten und Fusionsproteine mit Thymidinkinase- und Guanylatkinaseaktivität
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
EP1078093B1 (de) 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
EP1792988A3 (de) 1998-03-18 2007-08-22 Corixa Corporation Verbindungen und Verfahren für Therapie und Diagnose von Lungenkrebs
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6194178B1 (en) 1998-09-03 2001-02-27 Synsorb Biotech Inc. Method for the production of sialylated oligosaccharides
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
EP1036091B2 (de) 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
BR0008645A (pt) * 1999-03-03 2002-01-22 Univ Pennsylvania Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP2028190A1 (de) 1999-04-02 2009-02-25 Corixa Corporation Verbindungen und Verfahren für Therapie und Diagnose von Lungenkrebs
JP2002542800A (ja) * 1999-04-30 2002-12-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 変異体ヒトｃｄ８０および組成物およびその作製および使用法
US20030232060A1 (en) * 1999-07-28 2003-12-18 Smith Stephen M. Attenuated, doxycycline-inducible human immunodeficiency virus proviral molecular clones
KR20090085697A (ko) 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
ES2346637T3 (es) 2000-03-27 2010-10-19 Thomas Jefferson University Composiciones y metodos para identificar y marcar celulas cancerosas originadas en el tubo digestivo.
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
DE60134158D1 (de) 2000-06-28 2008-07-03 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US7488484B2 (en) * 2000-07-14 2009-02-10 The Trustees Of The University Of Pennsylvania Nucleic acid expression cassette encoding an HIV polyprotein comprising the ancillary gene products Vif, Vpu, and Nef
AU2001292728A1 (en) * 2000-09-18 2002-03-26 Thomas Jefferson University Compositions and methods for identifying and targeting stomach and esophageal cancer cells
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
WO2002029088A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
EP2706116A1 (de) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Bindungsdomäne-Immunglobulin-Fusionsproteine
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
WO2004009021A2 (en) 2002-07-18 2004-01-29 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ES2639812T3 (es) 2003-01-06 2017-10-30 Corixa Corporation Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
AU2004226345B2 (en) 2003-03-28 2011-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVA virus expressing modified HIV envelope, gag, and pol genes
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8008265B2 (en) 2003-06-13 2011-08-30 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
EP1661999A4 (de) 2003-08-01 2006-11-02 Inst Basic Med Sciences Pla Verfahren zur herstellung eines epitopen-chimärisches-gen-impfstoffs
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP2848942B1 (de) 2004-07-14 2017-03-08 The Regents of The University of California Biomarker zur Früherkennung von Eierstockkrebs
BRPI0513959A (pt) * 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EP1789552A2 (de) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Verfahren zur regulation der differenzierung und behandlung von multiplem myelom
EP1789438B1 (de) 2004-08-27 2015-04-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Rekombinante MVA-Viren die modifizierte HIV Clade A/G, Clade B und Clade C env, gag und pol Gene exprimieren
ES2540770T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
EP3312272B1 (de) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation der replikationsrate durch verwendung von seltener verwendeten synonymen kodonen
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
EP1701165A1 (de) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutischer und diagnostischer Gebrauch von TKTL1 sowie seiner Inhibitoren und Aktivatoren
US20090022755A1 (en) 2005-03-31 2009-01-22 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
EP1888634A2 (de) 2005-05-13 2008-02-20 Oxford Biomedica (UK) Limited Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
BRPI0613770A2 (pt) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
NI200800032A (es) 2005-07-25 2009-03-23 Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
ES2374458T3 (es) * 2006-01-13 2012-02-16 The Trustees Of The University Of Pennsylvania Vacunas y agentes inmunoterapéuticos que utilizan il-15 optimizada en codones, y métodos para utilización de los mismos.
EP1981905B1 (de) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia-impfstoff
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2049559B1 (de) * 2006-07-28 2012-12-19 The Trustees of the University of Pennsylvania Verbesserte hpv-impfstoffe
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
ES2588738T3 (es) * 2008-04-04 2016-11-04 The Trustees Of The University Of Pennsylvania Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas
CA2720168C (en) * 2008-04-04 2024-04-30 David B. Weiner Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
SI2132228T1 (sl) * 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
KR101609233B1 (ko) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
EP3124491B1 (de) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen sowie pharmazeutische zusammensetzungen die diese enthalten
KR20120093163A (ko) 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
JP5955771B2 (ja) 2009-10-22 2016-07-20 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法
CA2777705C (en) 2009-11-02 2019-03-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
EP2539354B1 (de) 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Für rantes kodierende nukleinsäuremoleküle sowie zusammensetzungen und verfahren damit
CN103314002B (zh) 2010-11-12 2016-09-07 宾夕法尼亚大学托管会 共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途
US9243041B2 (en) 2011-01-31 2016-01-26 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
CA2827080C (en) 2011-02-11 2022-09-20 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CA2841852C (en) 2011-07-11 2020-06-30 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
JP6041361B2 (ja) 2011-08-12 2016-12-07 メリアル インコーポレイテッド 生物学的製品、特にはワクチンの真空保存
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
CN107723299B (zh) 2011-10-12 2022-02-01 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
KR101913674B1 (ko) 2011-10-24 2018-10-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
AU2012352455B2 (en) 2011-12-12 2016-01-21 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
EP2791157A4 (de) 2011-12-12 2015-10-14 Univ Pennsylvania Zusammensetzungen mit verbesserten genetischen il-12-konstrukten und impfstoffen, immuntherapeutika damit und verwendungsverfahren dafür
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
HUE044612T2 (hu) 2012-05-04 2019-11-28 Pfizer Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
EP3586870A1 (de) 2013-03-12 2020-01-01 The Trustees Of The University Of Pennsylvania Verbesserte impfstoffe gegen humanes papillomavirus und verfahren zur verwendung davon
WO2014144521A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
MX2015011487A (es) 2013-03-15 2016-02-03 Univ Pennsylvania Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US20160083698A1 (en) 2013-04-19 2016-03-24 The Regents Of The University Of California Lone star virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
AU2014284360B9 (en) 2013-07-01 2019-10-24 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2015280433B2 (en) 2014-06-17 2020-10-08 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
JP2017521654A (ja) 2014-06-27 2017-08-03 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ ヒトペギウイルス２（ＨＰｇＶ−２）を検出するための組成物および方法
EP3270897A4 (de) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
JP7150611B2 (ja) 2016-01-08 2022-10-11 ジオバックス・インコーポレイテッド 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
BR112018013967A2 (pt) 2016-01-19 2019-02-05 Pfizer vacinas contra o câncer
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
CN109641044A (zh) 2016-05-30 2019-04-16 吉奥瓦科斯公司 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
CA3069363A1 (en) 2017-07-11 2019-01-17 Pfizer Inc. Immunogenic compositions comprising cea muc1 and tert
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
SG11202003443TA (en) 2017-11-24 2020-05-28 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof
PL3737397T3 (pl) 2017-12-13 2023-03-27 Inovio Pharmaceuticals, Inc. Szczepionki przeciwnowotworowe ukierunkowane do prame i ich zastosowania
CA3083528C (en) 2017-12-13 2023-09-12 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
KR102560562B1 (ko) 2017-12-13 2023-07-31 이노비오 파마수티컬즈, 인크. Muc16을 표적화하는 암 백신 및 이의 용도
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
JP7110369B2 (ja) 2018-02-23 2022-08-01 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｐｄ－１抗体及びその用途
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
JP7212138B2 (ja) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
BR112021004698A2 (pt) 2018-09-12 2021-06-01 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-tnfrsf9 e usos dos mesmos
JP7469305B2 (ja) 2018-11-19 2024-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｐｄ－１抗体およびその使用
CA3138461A1 (en) 2019-05-23 2020-11-26 Helene Bazin-Lee Vaccine adjuvants based on tlr receptor ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US4728609A (en) * 1983-01-10 1988-03-01 Hoffmann-La-Roche Inc. Recombinant growth hormone releasing factor
US4562155A (en) * 1983-05-19 1985-12-31 The Wistar Institute Of Anatomy And Biology Hybrid viral plasmid and microorganisms containing same

Also Published As

Publication number Publication date
JPS61289888A (ja) 1986-12-19
JPH07265085A (ja) 1995-10-17
EP0198328B1 (de) 1992-07-01
GB8508845D0 (en) 1985-05-09
EP0198328A3 (en) 1988-06-29
DK112586D0 (da) 1986-03-11
AU595190B2 (en) 1990-03-29
AU5539886A (en) 1986-10-09
CA1316849C (en) 1993-04-27
EP0198328A2 (de) 1986-10-22
US5017487A (en) 1991-05-21
DE3685833D1 (de) 1992-08-06
ZA862356B (en) 1986-11-26
DK112586A (da) 1986-10-05

Similar Documents

Publication Publication Date Title
DE3685833T2 (de) Dns-vakzine.
FI861830A0 (fi) Taetningsmaterial.
DE3668776D1 (de) Endotubus.
FI861726A0 (fi) Vaexthindrande skeppsbottenfaerg.
DE3683474D1 (de) Numerisierungsverfahren.
FI862109A (fi) Roerhanteringsapparat.
DE3669772D1 (de) Russblaeser.
DE3686178D1 (de) Malaria-impfstoff.
DE3687071D1 (de) Malaria-impfstoff.
DE3680606D1 (de) Loetapparat.
DE3681759D1 (de) Abschreckverfahren.
FI862787A (fi) Akterskydd foer isbrytande fartyg.
FI854404A0 (fi) Glidlagerkonstruktion.
FI861233A0 (fi) Efterbehandlad prostetisk anordning.
FI861877A (fi) Skyddshandske.
FI860327A (fi) Kammarvaegg.
FI861948A (fi) Fluoralkanderivat.
NO864764D0 (no) Vaksine.
FI854334A (fi) Flisanordning.
FI78594B (fi) Sjaelvgaoende skoerdetroeska.
FI850521A0 (fi) Baerplockningsanordning.
DE3679182D1 (de) Immunotestverfahren.
FI855043A0 (fi) Floedesmaetare.
FI853357L (fi) Haemtarbom.
FI853285A0 (fi) Behandlingsfoerfarande foer rundved.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee